All In Biotech

NDA 021464 · Pfizer

Vfend

Voriconazole · Oral, Injection

Last checked: Nov 19, 2026Latest source record: Nov 14, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Nov 14, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

153

39 Phase 3, 14 recruiting

FAERS reports

30,722

28,342 serious, 8,951 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 14, 2003 Original approval · Type 6 - New Indication (no longer used) ReviewLetterLabel
3 products under this application
  • VFEND · VORICONAZOLE 200MG · Tablet, Oral · Prescription
  • VFEND · VORICONAZOLE 200MG · Injectable, Injection · Prescription
  • VFEND · VORICONAZOLE 50MG · Tablet, Oral · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Voriconazole" as an intervention, any sponsor and status, largest first.

All 153 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,336
  • off label use2,510
  • drug interaction2,408
  • death1,481
  • pyrexia1,455
  • pneumonia1,359
  • condition aggravated1,157
  • bronchopulmonary aspergillosis1,066
  • aspergillus infection943
  • febrile neutropenia924
  • respiratory failure865
  • nausea796

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004315
2005322
2006418
2007446
2008429
2009618
2010855
2011876
20121,097
20131,062
20141,063
20151,201
20161,422
20171,997
20182,244
20192,497
20202,370
20212,184
20222,258
20231,992
20241,898
20251,869
20261,288

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vfend (Voriconazole)

2024 spending

$8K

Beneficiaries

12

19 claims

Per beneficiary

$635

$4.41 per unit

View as table
YearSpending
2020$42,158
2021$13,420
2022$8,554
2023$10,102
2024$7,623

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 407 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.